Milestone Scientific and Ordway Research Institute Agree to Develop Drugs for Administration Through CompuFlo(R) Systems
LIVINGSTON, N.J--(BUSINESS WIRE)--Milestone Scientific Inc. (OTC BB: MLSS), the recognized leader in advanced, computer-controlled drug delivery technologies, and Ordway Research Institute, a leading research and drug development organization, have agreed to develop drug formulations for precise targeted delivery of drugs to affected body parts, organs and cancerous tissue through Milestone’s patented CompuFlo® injection technology. Collaboration of the two organizations will facilitate the development by Ordway of nanoparticulate and other drug reformulations suitable for dispensing through specialized CompuFlo instruments which Milestone will develop. Drugs being developed by Ordway include those for treatment of arthritic joints, healing of wounds and destruction of tumeric and multisite cancers. Precise and targeted delivery of Ordway’s drug reformulations through Milestone’s instruments is believed by the parties to offer enhanced therapeutic benefits unavailable through systemic delivery and may lead to new patents being granted for reformulations of drugs in the public domain by Ordway and others. Under the agreement, Milestone will provide Ordway with prototype CompuFlo instruments to assist Ordway in its continuing development of its drug reformulations.